Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at Orange, California
Dates
study started
estimated completion
Principal Investigator
by Connie M. Rhee, MD, MSc

Description

Summary

Hypothyroidism, defined by elevated thyrotropin (TSH) levels, is a common endocrine complication of chronic kidney disease that has been associated with impaired quality of life and cardiovascular complications. While levothyroxine is one of the most frequently prescribed medications in chronic kidney disease patients, little is known about its efficacy and safety in this population. This study will investigate 1) whether levothyroxine adequately lowers thyrotropin (TSH) levels to therapeutic target ranges, and 2) if thyroid hormone replacement improves quality of life and cardiovascular markers, without leading to wasting in dialysis patients.

Keywords

Thyroid Disease, Kidney Diseases, Chronic, Kidney Diseases, Chronic Renal Insufficiency, Thyroid Diseases, Levothyroxine Sodium, Levothyroxine

Eligibility

You can join if…

Open to people ages 18-75

- Prevalent hemodialysis patients, elevated thyrotropin level, normal free thyroxine level.

You CAN'T join if...

  • Hyperthyroidism, active treatment with thyroid hormone replacement, prior thyroid malignancy, active pregnancy, active coronary ischemia or atrial fibrillation, osteoporosis, inability to provide consent without a proxy.

Location

  • University Dialysis Center of Orange accepting new patients
    Orange California 92868 United States

Lead Scientist at UC Irvine

  • Connie M. Rhee, MD, MSc
    Associate Professor, Medicine, School of Medicine. Authored (or co-authored) 252 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Irvine
ID
NCT03191188
Study Type
Interventional
Participants
Expecting 96 study participants
Last Updated